Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662740 · ClinicalTrials.gov registry record · Phase 3
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT00662740 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 220 participants.
The verdict
NCT00662740, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.
Interventions
- DRUG Placebo
- DRUG Salmeterol
- DRUG Tiotropium/Salmeterol QD
- DRUG Tiotropium/Salmeterol QD+ Salmeterol
- DRUG Tiotropium (Spiriva®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2008-04-15 |
| Est. Completion | 2008-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662740
The ClinicalTrials.gov registry entry for NCT00662740 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00662740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662740 about?
NCT00662740 is a clinical study titled "Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)". The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St Geor...
What is the current status of trial NCT00662740?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2008-04-15. Estimated completion is 2008-11-21.
What interventions are being tested in trial NCT00662740?
The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), Tiotropium/Salmeterol QD (DRUG), Tiotropium/Salmeterol QD+ Salmeterol (DRUG), Tiotropium (Spiriva®) (DRUG).
Who is sponsoring clinical trial NCT00662740?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.